A Phase 1 interventional study of metformin (Diabex) and metformin (Glucophage™) in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 231st largest by enrollment of the 287 interventional ones that give a count, is one of 20 that started in 2010, is one of 55 in phase 1, and was the 101st registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 20 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 228th largest by enrollment of the 280 interventional ones that give a count, is one of 42 that started in 2010, is one of 86 in phase 1, and was the 153rd registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To demonstrate the bioequivalence of 500 mg and 1000 mg Glucophage tablets manufactured by BMS relative to the respective strengths of 500 mg and 1000 mg Diabex tablets marketed in Australia by Alphapharm in the fed state
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
Drug: metformin (Diabex)
500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
Drug: metformin (Glucophage™)
1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
Drug: metformin (Diabex)
1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
Drug: metformin (Glucophage™)
Tablets, Oral, 500 mg, Once daily, single dose
Also known as: Diabex
Tablets, Oral, 500 mg, Once Daily, single dose
Also known as: Glucophage™
Tablets, Oral, 1000 mg, Once daily, single dose
Also known as: Glucophage™
Tablets, Oral, 1000 mg, Once daily, single dose
Also known as: Diabex
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Participants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).
Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE
Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.
Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Participants With Abnormal Physical Findings
Physical findings that were considered abnormal by the investigator.
Time frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
Participants With Abnormal Vital Sign Findings Reported as an AE
per investigator
Time frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology
Clinically significant was determined by the investigator.
Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry
Clinically significant was determined by the investigator.
Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis
Clinically significant was determined by the investigator.
Time frame: From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).
Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
A total of 28 participants who met all of the inclusion and none of the exclusion criteria were planned and enrolled in the study from a single site in the United States.
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 |
| Completed | 6 | 7 | 7 | 7 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Personal reason | 1 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 6 | 7 | 7 | 7 |
| Completed | 6 | 6 | 7 | 7 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Family emergency | 0 | 1 | 0 | 0 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
| ng*hr/mL | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) | 7062.76 ± 26.91 | 7187.14 ± 25.95 | 11577.85 ± 27.36 | 11424.73 ± 29.06 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
| ng/mL | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax) | 1013.57 ± 25.67 | 1019.59 ± 25.26 | 1635.30 ± 27.67 | 1593.20 ± 26.87 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| Participants | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Participants With atleast 1 Treatment-emergent AE | 6 | 2 | 5 | 6 |
| Discontinuations Due to AE | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.
| Participants | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Physical findings that were considered abnormal by the investigator.
| Participants | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Participants With Abnormal Physical Findings | 0 | 0 | 0 | 0 |
per investigator
| Participants | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Participants With Abnormal Vital Sign Findings Reported as an AE | 0 | 0 | 0 | 0 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
| hr | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax) | 3.25 ± 0.79 | 3.56 ± 0.80 | 3.22 ± 0.64 | 3.23 ± 0.80 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma
| hr | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2) | 13.2310 ± 5.3180 | 11.5349 ± 3.7633 | 12.6152 ± 4.2032 | 12.5268 ± 4.3137 |
Clinically significant was determined by the investigator.
| Participants | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology | 0 | 0 | 0 | 0 |
Clinically significant was determined by the investigator.
| Participants | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry | 0 | 0 | 0 | 0 |
Clinically significant was determined by the investigator.
| Participants | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis | 0 | 0 | 0 | 0 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
| ng*hr/mL | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage |
|---|---|---|---|---|
| Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) | 6907.06 ± 27.16 | 7078.70 ± 26.18 | 11305.27 ± 27.77 | 11129.89 ± 28.93 |
Collected over From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment C - 1000 mg Diabex | — | 0/27 (0%) | 5/27 (18.5%) |
| Treatment D - 1000 mg Glucophage | — | 0/27 (0%) | 6/27 (22.2%) |
| Treatment A - 500 mg Diabex | — | 0/28 (0%) | 6/28 (21.4%) |
| Treatment B - 500 mg Glucophage | — | 0/27 (0%) | 2/27 (7.4%) |
| Event | Treatment C - 1000 mg Diabex | Treatment D - 1000 mg Glucophage | Treatment A - 500 mg Diabex | Treatment B - 500 mg Glucophage |
|---|---|---|---|---|
| Vascular access complicationInjury, poisoning and procedural complications | 2/27 | 4/27 | 2/28 | 1/27 |
| DiarrhoeaGastrointestinal disorders | 2/27 | 2/27 | 1/28 | 0/27 |
| Abdominal painGastrointestinal disorders | 1/27 | 2/27 | 2/28 | 1/27 |
| HeadacheNervous system disorders | 0/27 | 1/27 | 1/28 | 0/27 |
| DizzinessNervous system disorders | 1/27 | 1/27 | 0/28 | 0/27 |
| SomnolenceNervous system disorders | 0/27 | 1/27 | 0/28 | 0/27 |
| NauseaGastrointestinal disorders | 0/27 | 1/27 | 0/28 | 0/27 |
| FlatulenceGastrointestinal disorders | 0/27 | 1/27 | 1/28 | 0/27 |
| Decreased appetiteMetabolism and nutrition disorders | 1/27 | 0/27 | 0/28 | 1/27 |
| PruritusSkin and subcutaneous tissue disorders | 0/27 | 1/27 | 0/28 | 0/27 |
| Age, Continuous(years) | All Enrolled and Treated Participants |
|---|---|
| Mean | 34.6 ± 11.05 |
| Sex: Female, Male(Participants) | All Enrolled and Treated Participants |
|---|---|
| Female | 12 |
| Male | 16 |
| Race/Ethnicity, Customized(Participants) | All Enrolled and Treated Participants |
|---|---|
| White | 24 |
| Black or African American | 4 |
| Race/Ethnicity, Customized(Participants) | All Enrolled and Treated Participants |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 18 |
| Height(Centimeter) | All Enrolled and Treated Participants |
|---|---|
| Mean | 169.54 ± 11.44 |
| Weight(kg) | All Enrolled and Treated Participants |
|---|---|
| Mean | 77.02 ± 15.88 |
| Body Mass Index(kg/m^2) | All Enrolled and Treated Participants |
|---|---|
| Mean | 26.58 ± 3.64 |
The record gives a start of Feb 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin